Drug delivery devices: nasal, pulmonary, injectable. US-listed access to the delivery-device node. Less pure than WST/STVN but diversified across delivery modalities.
Current stock research snapshot · 7/8/26 49 days old
ATRAptarGroup
Investment conviction●●○○○2 of 5 · current snapshot
Research target$157.39Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/8/26
Market cap$8.45BSnapshot value · 7/8/26
Biologics self-administration shift driving device demand; GLP-1 device attach rate; nasal/pulmonary drug delivery growth; connected device adoption.
Segment dilution (broader dispensing/closure businesses); less direct GLP-1 exposure than WST/STVN; competitive pressure in delivery devices.
Neutral — No significant X discussion found in the last 30 days. [X search Aug 2026]
Snapshot · 7/8/26🟢 Lean-Bull · ins-$4.6M · 13F 16+/8-×0.5 · short↓0.22
Snapshot · 7/8/26Timestamped research update
Deep research update
428 words · Updated Jul 25, 2026 · 3 sources
Research in development: this latest 428-word update is published for context while it is expanded toward the 1,000-word editorial standard.
AptarGroup makes drug delivery and consumer dispensing systems: nasal pumps, metered-dose inhaler valves, elastomer components for injectable primary packaging, plus beauty and closures dispensing. The Healthspan thesis driver is the Pharma segment, which sells into regulated drug-device systems.
FY2025 net sales were $3.777B, up 5.4% YoY from $3.583B; cost of sales was $2.372B, implying a 37.2% gross margin, and operating income was $501.0M, implying a 13.3% operating margin. Q1 2026 net sales were $982.9M, up 10.8% YoY from $887.3M; cost of sales was $631.0M, implying a 35.8% gross margin, and operating income was $107.5M, implying a 10.9% operating margin.
Aptar owns the qualification-and-regulatory bottleneck at the device layer of combination products. Once a drug sponsor has validated a pump, valve, or injector in its filing and manufacturing process, swapping suppliers is slow, costly, and regulated; Aptar monetizes that switching friction across pharma delivery systems.
- FY2025 Pharma represented ~46% of net sales and ~69% of adjusted EBITDA excluding non-allocated corporate costs, so Pharma contributes about 1.5x its sales share to EBITDA (69/46 = 1.50).
- Aptar said it has ~5,000 customers and no single customer or affiliated group accounted for >4% of 2025 net sales.
- The 2025 10-K says a "considerable amount of research and coordination" is required to qualify a pump for use with customer products, and that pharma manufacturing disruptions are difficult to remediate because of regulatory requirements, validation processes, and customer qualification timelines.
- The 2026-04-30 8-K EX-99.1 said Pharma reported sales increased 7% YoY; injectables sales increased 20% on GLP-1, biologics, and antithrombotics demand; and the pipeline for systemic nasal drug delivery continued to build.
The moat is not a single patent; it is the combination-product qualification stack: FDA/EU regulatory documentation, customer re-validation, clean-room manufacturing, and a global supply chain of specialized molds, resins, rubber components, and single-source processes. The hard constraint is replacement time and validation burden, not just unit cost.
- Pharma core sales can be lumpy: Q1 2026 core sales declined 1% even as reported sales rose on currency and acquisitions, and emergency-medicine destocking hit the quarter.
- The company itself flags exposure to single-source inputs, single-machine/single-mold manufacturing, and price competition across product lines.
- The vault does not appear to have a dedicated Healthspan technology note for drug delivery devices; that gap should be created or linked before the next review.
- How much of future growth comes from GLP-1 injectables vs. systemic nasal delivery, and which of those two has the longer qualification moat?
INTACT
Primary and supporting material
Sources
3 sources preserved from the latest qualified research update.